# Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

> **NCT07717242** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 80 (estimated)

## Conditions studied

- Bladder Urothelial Carcinoma
- Bladder Cancer

## Interventions

- **DRUG:** Disitamab vedotin
- **DRUG:** Toripalimab
- **DRUG:** Sitagliptin
- **DRUG:** Zeprumetostat
- **DRUG:** Tafolecimab
- **DRUG:** Ursodeoxycholic Acid
- **PROCEDURE:** Complete transurethral resection of bladder tumor

## Key facts

- **NCT ID:** NCT07717242
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-01-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-07-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717242, "Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*